Michael Didocha Joins Telix as Chief Financial Officer, Americas
Telix is delighted to announce the appointment of Michael Didocha as Chief Financial Officer for the Americas region.
Samantha McSherry Joins Telix as Director of Commercial Operations ANZ
Telix is delighted to announce that Samantha McSherry has joined Telix as Director of Commercial Operations for Australia and New Zealand.
Telix and Lightpoint Medical to Collaborate on Radioguided Surgery
Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI® in radioguided surgery (RGS)
Half Year Shareholder Update
Telix Pharmaceuticals Limited Announces Half-year Shareholder Update
AUDIO LINK NOT ATTACHED – Telix Half-Year Results 2021 and Company Update Conference Call
Telix announces Half-Year Results 2021 and provides shareholder update
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
Telix releases details of two ancillary studies under the ProstACT program, including a Phase II study in collaboration with GenesisCare.
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx in breast cancer.
Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being investigated in lung and ovarian cancers
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
Telix announces Phase II academic study of TLX66 in children with high-risk leukemia.